Federated Hermes, Inc. Nektar Therapeutics Transaction History

Federated Hermes, Inc.

$42.5 Billion
Q1 2024

A detailed history of Federated Hermes, Inc. transactions in Nektar Therapeutics stock. As of the latest transaction made, Federated Hermes, Inc. holds 1,256 shares of NKTR stock, worth $1,469. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,256

Previous 1,256 -0.0%

Holding current value

$1,469

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$0.42 - $0.57 $176 - $239	-420 Reduced 25.06%	1,256 $0
Q3 2023 Nov 13, 2023	SELL	$0.51 - $1.05 $380,256 - $782,880	-745,600 Reduced 99.78%	1,676 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.53 - $1.03 $611,359 - $1.19 Million	-1,153,508 Reduced 60.69%	747,276 $433,000
Q1 2023 May 08, 2023	BUY	$0.64 - $3.15 $30,645 - $150,834	47,884 Added 2.58%	1,900,784 $1.33 Million
Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $2.06 Million - $4.35 Million	1,015,835 Added 121.36%	1,852,900 $4.19 Million

Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $2.22 Million - $3.75 Million	729,087 Added 675.22%	837,065 $2.68 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $342,290 - $666,224	107,978 New	107,978 $410,000
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $221,646 - $376,779	-20,466 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $17,043 - $24,567	-1,304 Reduced 5.99%	20,466 $368,000
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $67,186 - $82,966	-4,067 Reduced 15.74%	21,770 $374,000
Q1 2021 May 13, 2021	SELL	$16.56 - $25.46 $2,699 - $4,149	-163 Reduced 0.63%	25,837 $517,000
Q4 2020 Feb 12, 2021	SELL	$15.77 - $19.03 $69,482 - $83,846	-4,406 Reduced 14.49%	26,000 $442,000
Q3 2020 Nov 12, 2020	SELL	$16.59 - $24.79 $241,600 - $361,016	-14,563 Reduced 32.38%	30,406 $504,000
Q2 2020 Aug 13, 2020	SELL	$16.86 - $23.44 $1.41 Million - $1.96 Million	-83,473 Reduced 64.99%	44,969 $1.04 Million
Q1 2020 May 13, 2020	SELL	$14.47 - $27.96 $13 Million - $25.1 Million	-896,089 Reduced 87.46%	128,442 $2.29 Million
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $8.37 Million - $12.2 Million	-527,569 Reduced 33.99%	1,024,531 $22.1 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $26.1 Million - $56.1 Million	1,545,508 Added 23445.21%	1,552,100 $28.3 Million
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $1,953 - $2,286	-63 Reduced 0.95%	6,592 $235,000
Q1 2019 May 10, 2019	BUY	$31.58 - $46.35 $5,431 - $7,972	172 Added 2.65%	6,655 $224,000
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $9.82 Million - $18.3 Million	-322,571 Reduced 98.03%	6,483 $213,000
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $6,225 - $9,177	-134 Reduced 0.04%	329,054 $20.1 Million
Q2 2018 Aug 10, 2018	SELL	$46.25 - $104.45 $10.9 Million - $24.5 Million	-234,913 Reduced 41.64%	329,188 $16.1 Million
Q1 2018 May 09, 2018	SELL	$57.4 - $108.44 $41.1 Million - $77.6 Million	-715,612 Reduced 55.92%	564,101 $59.9 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $5.79 Million - $15.2 Million	251,513 Added 24.46%	1,279,713 $0
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $18.3 Million - $24.7 Million	1,028,200	1,028,200 $24.7 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Nektar Therapeutics Transaction History